Meeting
2021 Gastrointestinal Cancers Symposium
ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC—A single-arm, multicenter, phase Ⅱ clinical trial.
Authors
Jin Yan
Department of Gastrointestinal Surgery, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China
Jin Yan , Li Zhang , Yongdong Jin , Yunwei Han , Hao Sun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiCTR1900028417
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 70)
DOI
10.1200/JCO.2021.39.3_suppl.70
Abstract #
70
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single-arm, multicenter, phase Ⅱ clinical trial—Update results from ALTER-C001.
First Author: Jin Yan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
First Author: Jin Yan
Poster
2019 ASCO Annual Meeting
Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).
First Author: Nong Xu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
First Author: Yue Liu